Thank you for subscribing!

Striving to Treat Inflammation Safely and More Effectively

A New Standard in Online Privacy and Security

How this company’s novel therapeutics might be the next big thing in treating autoimmune and more

In a world with countless pharmaceuticals, it can be hard to know that the treatment you’re on is the one that’s right for you. After all, you want the medicine you’re taking to work, but you don’t want it to be harmful to your health. More and more, people want therapeutic treatments that focus on harnessing the body’s natural ability to heal itself.

That’s exactly what Palatin Technologies (NYSE: PTN) is doing. Palatin develops novel therapeutics designed to help resolve the unmet needs of patients who live with a variety of inflammatory and autoimmune diseases.

It does it by creating potent compounds that work in tandem with the body’s ability to reduce inflammation via the melanocortin system. By leveraging its expert knowledge of the melanocortin system, Palatin is able to create solutions that offer an unprecedented approach to resolving inflammation allowing affected tissues time to heal. With a focus on ocular diseases, Palatin tackles full-scale therapeutics development, from drug discovery through FDA approval.


What is the Melanocortin System?

The melanocortin system is controlled by a group of five related receptors that receive inputs from hormones, nutrients, and afferent neural inputs. The system as a whole is essential to the body’s control of a variety of physiological functions, including inflammation, immune response, metabolism, steroid hormone production, and sexual function.

Palatin is focused on harnessing the melanocortin system in the following areas:

  • Brain – Melanocortin receptors in the hypothalamus affect weight maintenance and energy use. Melanocortin medicines can help patients reduce food intake and lose weight.
  • Eyes – Multiple cells and tissues in the eyes contain melanocortin receptors, providing the opportunity to use natural pathways to aid in reducing disease-associated inflammation.
  • Colon – Bowel inflammation can be reduced by locally engaging receptors found on intestinal epithelial cells immune cells.
  • Kidney – Podocytes essential kidney cells express the melanocortin receptor 1 (MCR1). By activating these cells via medicines that engage the MCR1, it may be possible to improve kidney function in a variety of kidney diseases.

Palatin addresses the needs of patients by researching, designing, and developing highly selective peptides and small molecule agonists designed to target specific melanocortin receptors. The goal is to develop novel medicines that provide relief to individuals who suffer from inflammation and autoimmune diseases.


First Out of the Gate

Palatin was the first company to develop this unique approach to the melanocortin system and get approval for novel melanocortin based medicine. The Palatin team is widely regarded as pioneers and experts in developing melanocortin based medicines.

It all started when the company developed Vyleesi®, a novel FDA approved medicine used to treat women living with generalized hypoactive sexual desire disorder (HSDD). This extremely successful treatment has helped countless women take control of their sex drive and improve their quality of life by extension.

The creation of Vyleesi® established Palatin as a leader in melanocortin system-based treatments and led them to move on to develop additional ​​groundbreaking therapeutics for inflammatory and autoimmune diseases, with a focus on ocular conditions.


Backed By Science

Once Palatin began to tap into the utility of melanocortin pathways as a method of developing novel medicines it kept that momentum going.

Palatin’s corporate presentation puts it best, “Our development arm builds on our proven success in bringing a melanocortin therapeutic from the lab to market by using our experience to propel our programs in ocular and autoimmune diseases from discovery to approval.”

In regard to its focus on ocular conditions, Palatin knows that the stakes are high. Over 20 million people in the United States suffer from dry eye disease (DED) and yet there are very few treatments to help relieve the irritation, redness, discharge, and blurred vision it causes. The scientists at Palatin see DED for what it is – a chronic, painful, debilitating inflammatory condition that requires a new, innovative course of treatment.

So Palatin got to work, developing a truly novel class of drugs that selectively bind to melanocortin receptors (MCR), that directly activate natural pathways that resolve disease inflammation in the eye. These drugs also have the advantage of better addressing the discomfort caused by inflammation in the tissues in the eye. The product is currently called the PL9643 ophthalmic solution, but we’ll get into this a little more later.

For now, we can’t go on without addressing Palatin’s advancement in autoimmune therapeutics. Melanocortin-based treatments have incredible potential to address autoimmune-related inflammation with far fewer complications than traditional broad immunosuppressant treatments.

The research work done by Palatin and academic laboratories demonstrate the potential of melanocortin based medicines as treatment for ulcerative colitis (UC). This is good news for the nearly 1 million people in the U.S. who suffer from autoimmune diseases, like UC, that result in chronic colon inflammation. Palatin is currently working on MCR1 agonist (PL8177), a delayed release, oral formula designed to maximize local treatment for diseased bowels while minimizing adverse systemic effects.


Feast Your Eyes on This

Recently, Palatin’s dry eye treatment, PL9643, entered Phase 3 clinical trials with the initiation of its pivotal MELODY-1 clinical study. During the course of the study in cities across the United States subjects will be enrolled to help evaluate the potential of PL9643 as a treatment for DED. Results of the study are expected to be released in the latter half of 2022.

“We are excited to initiate the MELODY-1 study of PL9643 in patients suffering from dry eye disease,” said Carl Spana, Ph.D., CEO and President of Palatin. “This is the second melanocortin peptide Palatin has advanced into Phase 3, demonstrating Palatin’s expertise and efficiency in melanocortin peptide development for indications with unmet medical need.”

The pivotal Phase 3 MELODY-1 clinical study is a multi-center, randomized, double-masked, and vehicle-controlled study. It’s designed to determine the efficacy and safety of the melanocortin agonist, PL9643 ophthalmic solution. The framework for the study is based on the successful results of Phase 2 and a successful end-of-phase meeting with the U.S. Food and Drug Administration. If all goes well, Palatin hopes to submit the treatment to the NDA within the first half of 2024.

And, given that the Phase 2 study demonstrated marked improvements in both the signs and symptoms of DED after only two weeks of treatment, with no safety signals and excellent tolerability, the future of Palatin’s PL9643 treatment is looking pretty bright.


First-in-Class Equals First in Patents

As a company pioneering the development of melanocortin based medicines , Palatin knows how important it is to protect its intellectual property. Recently, the U.S. Patent and Trademark Office issued a Notice of Allowance for Application No.: 16/927,347, which relates to the use of melanocortin peptides to decrease pro-inflammatory cytokine production and expression associated with cytokine storm.

Carl Spana, Ph.D., President and CEO of Palatin, spoke about the recent patent application saying, “We continue to strengthen our intellectual property surrounding our melanocortin receptor-1 peptide portfolio, particularly when early data suggest they can help resolve the overproduction and expression of pro-inflammatory cytokines associated with many diseases, including acute viral infections such as COVID-19. We continue to develop this technology as part of our diversified platform.”

Palatin’s platform is, indeed, diverse. With multiple programs in development, this patent is only one part of a family of patents that relates to melanocortin receptor-1 peptides and covers additional intellectual property relating to the use of high potency melanocortin receptor-1 peptides.

Speaking of patents, the United States Patent and Trademark Office issued Notices of Final Determination and Requirement for Election on a patent term extension for two U.S. patents covering Vyleesi®. Pursuant to the Drug Price Competition and Patent Term Restoration Act, U.S. patent 6,794,489 for Vyleesi® was extended for the maximum term and has an expiration date of June 28, 2025.


Innovation in Medicine

It’s clear that Palatin Technologies knows what it’s doing but, as an investor, you’re probably wondering how this vast experience translates to financial gain. So, let’s take a look at the financials.

Starting with Vyleesi®, Palatin announced that for the third quarter of 2021, gross product sales amounted to $1.4 million with a net product revenue of $159,482. This is a huge improvement over the previous quarter when gross product sales reached $809,100, with negative net product revenue of $(288,560).

Recently, Palatin announced results for the fiscal third quarter ending on March 31, 2022. Financial results from that quarter included the following highlights:

  • Net loss for the quarter was $7.6 million, compared to a net loss of $5.7 million for the same period in 2021.
  • As of March 31, 2022, the Company had cash and investments of $37.7 million, compared to $47.3 million as of December 31, 2021, and $60.1 million as of June 30, 2021, and no debt.
  • Vyleesi® (bremelanotide injection) / Hypoactive Sexual Desire Disorder (HSDD): Gross product sales increased 67%, net product revenue increased 200% and prescriptions increased 20%, over the prior quarter.

This most recent quarter also brought significant results from the company’s Vyleesi Hypoactive Sexual Desire Disorder (HSDD) treatment for women. The goal of the Vyleesi program is to demonstrate product value in the marketplace with an objective of re-licensing the U.S. rights to a committed women’s healthcare company.

For the quarter ended March 31, 2022, Vyleesi achieved:

  • Gross product sales increased 67% over the prior quarter, decreased 27% over the comparable quarter in 2021.
  • Net product revenue increased 200% over the prior quarter, increased 144% over the comparable quarter in 2021.
  • Total prescriptions dispensed increased 20% over the prior quarter, flat compared to the comparable quarter in 2021.
  • Refill rates, commercial insurance reimbursement, and net revenue per prescription dispensed increased over the prior quarter and comparable quarter in 2021.

Investors, patients, and healthcare providers can learn more about HSDD and Vyleesi at and

Some other notable product highlights include:

  • The initiation of the pivotal Phase 3 clinical program in DED patients in December 2021, using its PL9643 melanocortin agonist.
  • Reporting positive effects of PL8177 on treating ulcerative colitis in an animal disease model, including genomic data characterizing the anti-inflammatory effects of melanocortin agonists.
  • Planning for a phase 2 oral formulation study of PL8177 in UC patients that are currently scheduled to start in the first half of the calendar year 2022.
  • The presentation of the protective effects of PL8331 and PL9654 in mouse models of retinopathy, at the 2021 Annual Meeting of the American Society of Retina Specialists.
  • Plans to continue to strengthen its R&D department with key appointments who have demonstrated a high level of expertise in their fields.

Believe us, we understand that this is a lot of complex medical data. What it all comes down to is this: Palatin has the experience and leadership to be successful.

It’s one of the leading companies creating medicines based on the melanocortin system utilizing the body’s natural defenses to create a well-rounded, safe, and efficient treatment for a variety of inflammatory and autoimmune diseases.

The Company has a science-driven approach to bringing potential treatments to patients by responding to the challenges inherent to drug design and development with agility, expertise, and determination.

Palatin’s innovation is unmatched, their grit unparalleled, and their future is undeniably promising. As Palatin Technologies (NYSE: PTN) continues to explore uncharted waters, smart investors would do well to jump on board this ship before too many others do.


PR and News


Management Team: 

Carl Spana, PhD

CEO, President and Director

Carl Spana, the co-founder of Palatin, has been the Chief Executive Officer and President since June 14, 2000. He has been a director of Palatin since June 1996 and has been a director of their wholly-owned subsidiary, RhoMed Incorporated, since July 1995. From June 1996 through June 14, 2000, Dr. Spana served as an executive vice president and our chief technical officer.

From June 1993 to June 1996, Dr. Spana was vice president of Paramount Capital Investments, LLC, a biotechnology and biopharmaceutical merchant banking firm, and of The Castle Group Ltd., a medical venture capital firm. Through his work at Paramount Capital Investments and The Castle Group, Dr. Spana co-founded and acquired several private biotechnology firms.

From July 1991 to June 1993, Dr. Spana was a research associate at Bristol-Myers Squibb, a publicly held pharmaceutical company, where he was involved in scientific research in the field of immunology. Dr. Spana received his Ph.D. in molecular biology from Johns Hopkins University and his BS in biochemistry from Rutgers University.


Stephen T. Wills, CPA, MST

Chief Financial Officer, Chief Operating Officer, and Treasurer and Secretary

Mr. Wills has served on the board of directors of MediWound Ltd. (Nasdaq: MDWD), a biopharmaceutical company focused on treatment in the fields of severe burns, chronic and other hard to heal wounds, since April 2017, and as Chairman since January 2018, and also has served on the board of directors of Gamida Cell Ltd. (Nasdaq: GMDA), a leading cellular and immune therapeutics company, since March 2019 (audit, compensation, and finance committee member), and of Amryt Pharma, a biopharmaceutical company focused on developing and delivering treatments to help improve the lives of patients with rare and orphan diseases, since September 2019 (chairman of audit committee and member of the compensation and finance committee).

Mr. Wills has also served on the board of trustees and executive committee of The Hun School of Princeton, a college preparatory day and boarding school, since 2013, and as its Chairman since June 2018. Mr. Wills served as Executive Chairman and Interim Principal Executive Officer of Derma Sciences, Inc., a provider of advanced wound care products, from December 2015 to February 2017, when Derma Sciences was acquired by Integra Lifesciences (Nasdaq: IART).

Previously, Mr. Wills served on the board of directors of Derma Sciences as the lead director and chairman of the audit committee from June 2000 to December 2015. Mr. Wills served as the Chief Financial Officer of Derma Sciences from 1997 to 2000. Mr. Wills served as the President and Chief Operating Officer of Wills, Owens & Baker, P.C., a public accounting firm, from 1991 to 2000. Mr. Wills, a certified public accountant, earned his Bachelor of Science in accounting from West Chester University, and a Master of Science in taxation from Temple University.


Stephen A. Slusher

Chief Legal Officer and Assistant Secretary

Previously, Stephen A. Slusher was a partner in a boutique intellectual property law firm in Albuquerque, New Mexico, Peacock Law PC, where he remains of counsel. Earlier in his career, he was involved in the creation of several biotechnology companies. He is a registered patent attorney and licensed attorney and has developed the intellectual property strategy for Palatin. Mr. Slusher received his B.A. degree from St. John’s College in Santa Fe, New Mexico, and his J.D. degree from the University of New Mexico.


Michael B. Raizman, M.D.

Chief Medical Officer

Michael B. Raizman is a cornea and cataract specialist at Ophthalmic Consultants of Boston and the New England Eye Center at Tufts Medical Center.

Dr. Raizman received his medical training at the University of Michigan and Harvard Medical School. He completed two fellowships at the Massachusetts Eye & Ear Infirmary, followed by three years of post-doctoral research at Harvard Medical School, funded by grants from the National Institutes of Health.

Dr. Raizman served on the full-time faculty at Harvard Medical School from 1988-1991. Dr. Raizman is an Associate Professor of Ophthalmology at Tufts University School of Medicine, where he has directed the Corneal Fellowship Program and the Cornea and Cataract Service since 1992. In that capacity, he has trained over 50 Cornea Fellows. He is on the medical staff of the Massachusetts General Hospital, Massachusetts Eye and Ear, and Tufts Medical Center.

Dr. Raizman has pioneered many advancements in the field of cornea and inflammatory eye disease. Since the early 1990s has led to advances in laser therapy of eye disorders, post-operative inflammation, and more recently the development of techniques in corneal crosslinking. He has participated in over 100 clinical trials and published the results of trials, primarily in corneal surgery and ocular drug therapy.

Dr. Raizman has served on multiple medical and advisory boards as well as journal editorial boards. He received a Senior Honor Award from the American Academy of Ophthalmology for his scientific presentations and educational activities. He has delivered over 350 invited lectures throughout the United States, Canada, Mexico, South America, Europe, and Asia and has been a visiting professor at the medical schools of Columbia University, UCLA, University of Michigan, University of Texas, Loyola, Jefferson Medical College, and others.

He delivered a distinguished alumnus lecture at the University of Michigan and was the invited speaker at the 30-year reunion of his Harvard ophthalmology class. He has delivered multiple named lectures and authored over 100 peer-reviewed medical journal articles, as well as numerous book chapters and books. In 2020, he was named the “Ophthalmologist of the Year” by the National Keratoconus Foundation.


Who are we and what do we do? We are paid advertisers, also known as stock touts or stock promoters, who disseminate favorable information (the “Information”) about publicly traded companies (the “Profiled Issuers”). How is the Information published? We publish the Information on our Website, in newsletters, audio services, live interviews, featured “research” reports, on message boards and in email communications for specific time periods that are agreed upon between us and the Profiled Issuer or third party paying us. Our publication of the Information is known as a “Campaign”. Will everyone receive the Information at the same time? No. The Information may be sent to potential investors at different times that are minutes, hours, days or even weeks apart. How is a potential investor impacted if he/she receives the Information later than other investors? Typically, the trading volume and price of a Profiled Issuer’s securities increases after the Information is provided to the first group of investors. Therefore, the later an investor receives the Information, the more likely it is that he/she may suffer increased trading losses if he/she purchases the securities of a Profiled Issuer. What will happen when the Campaign ends? Most, if not all, of the Profiled Issuers are penny stocks that are illiquid and whose securities are subject to wide fluctuations in trading price and volume. During the Campaign the trading volume and price of the securities of each Profiled Issuer will likely increase significantly. When the Campaign ends, the volume and price of the Profiled Issuer will likely decrease dramatically. As a result, investors who purchase during the Campaign and hold shares of the Profiled Issuer when the Campaign ends will probably lose most, if not all, of their investment. Why do we publish only favorable Information? We only publish favorable information because we are compensated to publish only favorable information. Why don’t we publish negative Information? We don’t publish negative information because we are not paid to publish negative information. We are paid to publish only favorable information. Is the Information complete, accurate, truthful or reliable? No. The Information is a snapshot that provides only positive information about the Profiled Issuers. The Information consists of only positive content. We do not and will not publish any negative information about the Profiled Issuers; accordingly, investors should consider the Information to be one-sided and not balanced, complete, accurate, truthful or reliable. What we do not do? We do not publish negative information about the Profiled Issuers. We do not verify or confirm any portion of the Information. We do not conduct any due diligence, nor do we research any aspect of the Information including the completeness, accuracy, truthfulness or reliability of the Information. We do not review the Profiled Issuers’ financial condition, operations, business model, management or risks involved in the Profiled Issuer’s business or an investment in a Profiled Issuer’s securities. Where does the Information come from? The Information is provided to us by the Profiled Issuers and/or the person who hires us. We may also obtain the Information from publicly available sources such as the OTC Markets, Google, NASDAQ, NYSE, the Securities and Exchange Commission’s Edgar database or other available public sources. If we say we make “stock picks,” are those picks our own? No, they are not. We are compensated to advertise the securities we are told to advertise. What will happen if an investor relies on the Information? If an investor relies on the Information in making an investment decision it is highly probable that the investor will lose most, if not all, of his or her investment. Investors should not rely on the Information to make an investment decision. Who pays us to publish the Information? The source of our compensation varies depending upon the particular circumstances of the Campaign. We are compensated by the Profiled Issuers, third party shareholders and other parties related to the Profiled Issuers such as officers and/or directors who will derive a financial or other benefit from an increase in the trading price and/or volume of a Profiled Issuer’s securities. The nature and amount of compensation we receive for publishing the Information about each Profiled Issuer and our ownership of each Profiled Issuer is set forth below under the heading captioned, “What we are compensated”. What warranties do we make about the Information? None. We make no warranty or representation about the Information, including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable and as such, your use of the Information is at your own risk. The Information is provided as is without limitation. What we are not. We are not and do not act in the capacity of any of the following; as such, you should not construe our activities as involving any of the following:
  • An independent adviser or consultant;
  • A fortune teller;
  • An investment adviser or an entity engaging in activities that would be deemed to be providing investment advice that requires registration either at the federal or state level;
  • A broker-dealer or an individual acting in the capacity of a registered representative or broker;
  • A stock picker;
  • A securities trading expert;
  • A securities researcher or analyst;
  • A financial planner or one who engages in financial planning;
  • A provider of stock recommendations;
  • A provider of advice about buy, sell or hold recommendations as to specific securities; or
  • An agent offering or securities for sale or soliciting their purchase.
Are risks in this disclaimer the only risks investors should be aware of? No. There are numerous risks associated with each Profiled Issuer and investors should undertake a full review of each Profiled Issuer with the assistance of their financial, legal, and tax advisers prior to purchasing the securities of any Profiled Issuer. What conflicts of interest do we have in publishing the Information? We are not objective or independent and have multiple conflicts of interest. The Profiled Issuers and parties hiring us have conflicts of interest. Our publication of the Information involves actual and material conflicts of interest including but not limited to the following:
  • We receive monetary and/or securities compensation in exchange for publishing the (favorable) Information about the Profiled Issuers;
  • We do not publish any negative information whatsoever about the Profiled Issuers;
  • We may own a Profiled Issuer’s securities that we acquired from the Profiled Issuer, third parties or from our own open market purchases before, during or after the Campaign and we may sell these securities during the Campaign while publishing the (favorable) information that instructs investors to purchase. Our selling of a Profiled Issuer’s securities will likely cause investors to suffer losses;
  • A short time after we acquire a Profiled Issuer’s payment via cash or securities, we may publish the (favorable) Information about the Profiled Issuer advising others, including you, to purchase; and while doing so, we may sell the Profiled Issuer’s securities we acquired during our public dissemination of the Information causing us to profit while you suffer a loss;
  • Parties holding a Profiled Issuer’s securities, including those who engage our services and/or compensate us, will sell their shares of the Profiled Issuer while we are publishing the (favorable) Information.
Who is responsible if an investor relies on the Information? The investor. We are not responsible or liable for any person’s use of the Information or any success or failure that is directly or indirectly related to such person’s use of the Information because we have specifically stated that the information is not reliable and should not be relied upon for any purpose. We are not responsible for omissions or errors in the Information, and we are not responsible for actions taken by any person who relies upon the Information. What do we urge potential investors to do? We urge Investors to conduct their own in-depth investigation of the Profiled Issuers with the assistance of their legal, tax and investment advisers. An investor’s review of the Information should include but not be limited to the Profiled Issuer’s financial condition, operations, management, products or services, trends in the industry and risks that may be material to the profiled Issuer’s business and other information he and his advisers deem material to an investment decision. An investor’s review should include, but not be limited to a review of available public sources and information received directly from the Profiled Issuers or from websites such as Google, OTC Markets, NASDAQ, NYSE, or other available public sources. Why is this Disclaimer being provided? We are providing you with this disclaimer because we are publishing advertisements about penny stocks. Because we are paid to disseminate the Information to the public about securities, we are required by the securities laws including Section 10(b) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 thereunder, and Section 17(b) of the Securities Act of 1933, as amended (the “Securities Act”), to specifically disclose our compensation as well as other important information, This information includes that we may hold, as well as purchase and sell, the securities of a Profiled Issuer before, during and after we publish favorable Information about the Profiled Issuer. We may urge investors to purchase the securities of a Profiled Issuer while we sell our own shares. The anti-fraud provisions of federal and state securities laws require us to inform you that we may engage in buying and selling of Profiled Issuer’s securities before, during and after the Campaigns. What are other risks that investors should be aware of? Any investment in the Profiled Issuers involves a high degree of risk and uncertainty. The securities may be subject to extreme volume and price volatility, especially during the Campaigns. Favorable past performance of a Profiled Issuer does not guarantee future results. If you purchase the securities of the Profiled Issuers, you should be prepared to lose your entire investment. Some of the risks involved in purchasing securities of the Profiled Issuers include, but are not limited to the risks stated below.
  • We do not endorse, independently verify or assert the truthfulness, completeness, accuracy or reliability of the Information. We conduct no due diligence or investigation whatsoever of the Information or the Profiled Issuers and we do not receive any verification from the Profiled Issuer regarding the Information we disseminate.
  • If we publish any percentage gain of a Profiled Issuer from the previous day close in the Information, it is not and should not be construed as an indication that the future stock price or future operational results will reflect gains or otherwise prove to be advantageous to your investment.
  • The Information may contain statements asserting that a Profiled Issuer’s stock price has increased over a certain period of time which may reflect an arbitrary period of time, and is not predictive or of any analytical quality; as such, you should not rely upon the (favorable) Information in your analysis of the present or future potential of a Profiled Issuer or its securities.
  • The Information should not be interpreted in any way, shape, form or manner whatsoever as an indication of the Profiled Issuer’s future stock price or future financial performance.
  • You may encounter difficulties determining what, if any, portions of the Information are material or non-material, making it all the more imperative that you conduct your own independent investigation of the Profiled Issuer and its securities with the assistance of your legal, tax and financial advisor.
  • We or other stock promoters may receive free trading shares as compensation or we may acquire such shares in open market transactions before and during the Campaigns, and we may sell the shares we acquire at any time, even during the Campaigns while publishing the Favorable Information. When we sell the shares of the Profiled Issuers that we hold, the price at which investors can sell their shares will dramatically decrease and will likely cause investors to suffer trading losses.
  • We may sell securities of the Profiled Issuers for less than target prices set forth in the Information, and we may profit by selling our securities during the Campaigns while investors encounter losses.
  • When we acquire, purchase or sell the securities of the Profiled Issuers, it may (a) cause significant volatility in the Profiled Issuer’s securities; (b) cause temporary but unrealistic increases in volume and price of the Profiled Issuer’s securities; (c) if selling, cause the Profiled Issuer’s stock price to decline dramatically; and (d) permit us to make substantial profits while investors who purchase during the Campaign experience significant losses.
  • The securities of the Profiled Issuers are high risk, unstable, unpredictable and illiquid which may make it difficult for investors to sell their securities of the Profiled Issuers.
  • If we are compensated in improperly free trading securities of the Profiled Issuers, either directly or indirectly from persons who claim to be non-affiliates of such Profiled Issuer, we and the Profiled Issuer or third party could be subject to SEC Enforcement Action, including allegations of an illegal distribution in violation of Section 5(a) and 5(c) of the Securities Act.
  • We may hire third party service providers and stock promoters to electronically disseminate live news regarding the Profiled Issuers, yet we have no control over the content of and do not verify the information that the Profiled Issuers and/or third party service providers publish. These third party service providers are likely compensated for providing positive information about the Issuer and fail to disclose their compensation to you.
If a Profiled Issuer is an SEC reporting company, it could be delinquent (not current) in its periodic reporting obligations (i.e., in its quarterly and annual reports), or if it is an OTC Markets Pink Sheet quoted company, it may be delinquent in its Pink Sheet reporting obligations, which may result in OTC Markets posting a negative legend pertaining to the Profiled Issuer at, as follows: (i) “Limited Information” for companies with financial reporting problems, economic distress, or that are unwilling to file required reports with the Pink Sheets; (ii) “No Information,” which characterizes companies that are unable or unwilling to provide any disclosure to the public markets, to the SEC or the Pink Sheets; and (iii) “Caveat Emptor,” signifying buyers should be aware that there is a public interest concern associated with a company’s illegal spam campaign, questionable stock promotion, known investigation of a company’s fraudulent activity or its insiders, regulatory suspensions or disruptive corporate actions. If the Information states that a Profiled Issuer’s securities are consistent with the future economic trends or even if your independent research indicates that, you should be aware that economic trends have their own limitations, including: (a) that economic trends or predictions may be speculative; (b) consumers, producers, investors, borrowers, lenders and government may react in unforeseen ways and be affected by behavioral biases that we are unable to predict; (c) human and social factors may outweigh future economic trends that we state may or will occur; (d) clear cut economic predictions have their limitations in that they do not account for the fundamental uncertainty in economic life, as well as ordinary life; (e) economic trends may be disrupted by sudden jumps, disruptions or other factors that are not accounted for in economic trends analysis; in other words, past or present data predicting future economic trends may become irrelevant in light of new circumstances and situations in which uncertainty becomes reality rather than predicted economic outcome; or (f) if the trend predicted involves a single result, it ignores other scenarios that may be crucial to make a decision in the event of unknown contingencies. The Information is presented only as a brief snapshot of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities. You should consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at, or other electronic media, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the; (c) obtaining and reviewing publicly available information contained in commonly known search engines such as Google; and (d) consulting investment guides at and You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and the OTC Markets and/or have negative legends and designations at What we were paid to advertise the Profiled Issuers. The details of our compensation and the period of the Campaign is set forth below.
  • Name of Issuer & Ticker Symbol - Palatin Technologies, Inc. (PTN)
  • Amount & Form of Compensation - $90,000 in USD
  • Who Paid for the Campaign & Position with Company if any - Palatin Technologies, Inc. (PTN)
  • Period of Campaign - 02/22/2022 - 05/22/2022

Related Post

Register to Download the Presentation

Go to website
Go to top